About Us
Biofilm Disruption for Blepharitis and Dry Eye Disease Treatment
Inoculus is pharmaceutical startup based in the Research Triangle of North Carolina, pioneering transformative therapies that target and prevent the growth of Staph. biofilms on the eyelid. Our products disrupt the inflammatory cycle of chronic dry eye disease, paving the way for healthier eyes and an enhanced quality of life.
Background
Blepharitis and chronic dry eye disease are common ocular disorders that significantly impact the quality of life of millions worldwide. Current treatment options for these conditions are limited and often fail to address the underlying causes, such as biofilm formation on the eyelid. Staphylococcus bacteria, particularly Staphylococcus aureus, plays a significant role in the pathogenesis of blepharitis and chronic dry eye disease. These bacteria have a propensity to form biofilms on the eyelid, which are resistant to topical antibiotics and immune cell infiltration. Furthermore, S. Aureus is known to release a cascade of exotoxins that lead to inflammation, especially when they reach a state of quorum sensing gene activation, exacerbating the condition. Inoculus Ventures has developed a revolutionary enzymatic product, designed to effectively remove and inhibit biofilm growth on the eyelid, offering a promising solution for treating blepharitis and chronic dry eye disease